Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07515027

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Led by Shanghai Chest Hospital · Updated on 2026-04-13

204

Participants Needed

1

Research Sites

38 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.

CONDITIONS

Official Title

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Body mass index (BMI) between 18 and 30 kg/m²
  • Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection
  • Expected to receive postoperative opioid pain medication and have an Apfel risk score of 3 or higher
  • Normal lung function without severe cardiovascular, liver, or kidney problems
  • No infection near acupuncture sites
  • Provided voluntary written informed consent
Not Eligible

You will not qualify if you...

  • Severe systemic diseases like serious heart, liver, or kidney problems, or poor lung function
  • Cognitive dysfunction or psychological disorders
  • Previous esophageal or stomach surgery
  • Allergic reactions to acupuncture or study medications
  • Severe infection or past surgery near acupuncture sites
  • Pregnant or breastfeeding women
  • Long-term opioid use
  • Conversion to open surgery during procedure
  • Received acupuncture treatment within 1 month before enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Chest Hospital

Shanghai, China

Actively Recruiting

Loading map...

Research Team

D

Deputy Chief Physician

CONTACT

C

Chief Physician

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here